This study illustrates the inter-linkages between different market-shaping actors and interventions and the tensions between sometimes conflicting market impact goals. These interdependencies need to be considered when donors seek to measure GHI impact on value-for-money in the health technology space. Price sometimes dominates these discussions, but price needs to be seen in relation to the other objectives driving health outcomes and also the importance of seeking dynamic as well as static improvements in health technology markets.

Specific findings are reported on for Tuberculosis, long-lasting insecticidal nets, antiretrovirals and vaccines.